Genetic predictors of an unfavorable course of severe congenital neutropenia in patients with ELANE gene mutation
- Authors: Deordieva E.A.1, Varlamova T.V.1, Raikina E.V.1, Shcherbina A.Y.1
- 
							Affiliations: 
							- Federal Research Center of Pediatric Hematology, Oncology, and Immunology named after Dmitry Rogachev
 
- Issue: Vol 15, No 1 (2016)
- Pages: 41-45
- Section: ИММУНОЛОГИЯ
- Submitted: 19.09.2018
- Published: 19.03.2016
- URL: https://hemoncim.com/jour/article/view/147
- DOI: https://doi.org/10.24287/1726-1708-2016-15-1-41-45
- ID: 147
Cite item
Full Text
Abstract
Severe congenital neutropenia (SCN) is a rare genetically determined disease with disruption of granulocyte maturation in bone marrow, resulting in a high risk of life-threatening infections. The disease is caused by ELANE gene mutation in the majority (60-80%) of patients. Our study confirms the data of the Severe Congenital Neutropenia International Registry: we have demonstrated an association of ELANE gene mutations (in C151 and G214 positions) with a particularly severe disease course, manifesting by resistance to therapy with granulocyte colony-stimulating factor and the development of myelodysplastic syndrome.
			                Keywords
							                        	                        								дети,															врожденная нейтропения,															циклическая нейтропения,															мутация в гене ELANE,															тяжесть течения,															гранулоцитарный колониестимулирующий фактор,															острый миелоидный лейкоз,															миелодиспластический синдром,															children,															congenital neutropenia,															cyclic neutropenia,															ELANE gene mutation,															severe course,															granulocyte colony-stimulating factor,															acute myeloid leukemia,															myelodysplastic syndrome							                                        	
			                About the authors
Ekaterina A. Deordieva
Federal Research Center of Pediatric Hematology, Oncology, and Immunology named after Dmitry Rogachev
							Author for correspondence.
							Email: deor2005@yandex.ru
				                					                																			                												                	Russian Federation													
Tatyana V. Varlamova
Federal Research Center of Pediatric Hematology, Oncology, and Immunology named after Dmitry Rogachev
														Email: varltatwell@mail.ru
				                					                																			                												                	Russian Federation													
Elena V. Raikina
Federal Research Center of Pediatric Hematology, Oncology, and Immunology named after Dmitry Rogachev
														Email: e_raikina@inbox.ru
				                					                																			                												                	Russian Federation													
Anna Yu. Shcherbina
Federal Research Center of Pediatric Hematology, Oncology, and Immunology named after Dmitry Rogachev
														Email: shcher26@hotmail.com
				                					                																			                												                	Russian Federation													
References
Supplementary files
 
				
			 
					 
						 
									
 
  
  
  Email this article
			Email this article 

